Full-year guidance was raised in Q1 2026, with CFO Bueker stating revenue is "up 40 basis points from our previous guide," while Q4 2025 positioned 2026 around the initial guide and a framework that ...

Breakthrough research focus: Trials are exploring optimal dialysis dosing, fluid removal in AKI, and liberalized diets for dialysis patients while testing new therapies for glomerular conditions.

Accord Healthcare, Inc., a leading generic pharmaceutical company, committed to improving access to affordable medicines, today announced the relaunch of Tadalafil Tablets, an FDA-approved ...

A new beta build of Orion for Linux is available, with the v0.3 update described by its makers, the search company Kagi, as ...

First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. Read ...

As we depart spring practice, it's time to take stock of the Longhorns roster today. We'll start with the offensive x-factors ...

Will Mike Vrabel's offseason drama affect the product on the field? From SpyGate to DeflateGate, the Patriots are no ...

The Los Angeles Chargers have cemented their pass-catching corps, and Mike McDaniel delivered a resounding endorsement of their weaponry.

Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative ...

Shijiazhuang No.4 Pharmaceutical (02005.HK) announced that it has obtained a drug production registration approval from the ...

For millions of viewers growing up in the late 1960s, the classic TV sitcom Family Affair offered something comforting and ...